Kodiak Sciences/$KOD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kodiak Sciences
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Ticker
$KOD
Sector
Health
Primary listing
Employees
113
Headquarters
Website
Kodiak Sciences Metrics
BasicAdvanced
$432M
-
-$3.62
2.43
-
Price and volume
Market cap
$432M
Beta
2.43
52-week high
$11.42
52-week low
$1.92
Average daily volume
553K
Financial strength
Current ratio
4.621
Quick ratio
4.497
Long term debt to equity
52.086
Total debt to equity
62.144
Profitability
EBITDA (TTM)
-181.257
Management effectiveness
Return on assets (TTM)
-34.10%
Return on equity (TTM)
-108.92%
Valuation
Price to book
3.96
Price to tangible book (TTM)
3.96
Price to free cash flow (TTM)
-4.018
Free cash flow yield (TTM)
-24.89%
Free cash flow per share (TTM)
-2.041
Growth
Earnings per share change (TTM)
-18.38%
3-year earnings per share growth (CAGR)
-15.57%
What the Analysts think about Kodiak Sciences
Analyst ratings (Buy, Hold, Sell) for Kodiak Sciences stock.
Bulls say / Bears say
Kodiak ended Q1 2025 with $138.9 million in cash and cash equivalents, providing a runway into 2026 and supporting ongoing Phase 3 trials.
Upon successful topline data from Phase 3 GLOW2 and DAYBREAK, Kodiak plans to file a single BLA in 2026 for three indications, potentially accelerating market entry and revenue.
Early Phase 1b APEX data presented in January 2025 demonstrated strong treatment responses in MESI patients with KSI-101, highlighting the promise of its inflammation-targeting program.
In Q1 2025, Kodiak reported a net loss of $57.5 million or $1.09 per share, with R&D expenses up 45.8% year-over-year, underscoring high cash burn.
HC Wainwright cut its Q2 2025 EPS forecast to ($1.09) from ($0.99), reflecting a dim near-term profitability outlook and cautious analyst sentiment.
Shares have plunged approximately 60% year-to-date, indicating significant investor skepticism around clinical success and funding risk.
Data summarised monthly by Lightyear AI. Last updated on 22 Jul 2025.
Kodiak Sciences Financial Performance
Revenues and expenses
Kodiak Sciences Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kodiak Sciences stock?
Kodiak Sciences (KOD) has a market cap of $432M as of August 08, 2025.
What is the P/E ratio for Kodiak Sciences stock?
The price to earnings (P/E) ratio for Kodiak Sciences (KOD) stock is 0 as of August 08, 2025.
Does Kodiak Sciences stock pay dividends?
No, Kodiak Sciences (KOD) stock does not pay dividends to its shareholders as of August 08, 2025.
When is the next Kodiak Sciences dividend payment date?
Kodiak Sciences (KOD) stock does not pay dividends to its shareholders.
What is the beta indicator for Kodiak Sciences?
Kodiak Sciences (KOD) has a beta rating of 2.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.